RPRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RPRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2025-03-16), the Trailing Annual Dividend Yield of Royalty Pharma is 2.59%.
Warning Sign:
Royalty Pharma PLC stock dividend yield is close to 1-year low.
The historical rank and industry rank for Royalty Pharma's Dividend Yield % or its related term are showing as below:
During the past 8 years, the highest Dividend Yield of Royalty Pharma was 3.34%. The lowest was 0.31%. And the median was 1.87%.
Royalty Pharma's Dividend Payout Ratio for the three months ended in Dec. 2024 was 0.60.
During the past 8 years, the highest Dividend Payout Ratio of Royalty Pharma was 0.57. The lowest was 0.33. And the median was 0.42.
As of today (2025-03-16), the Forward Dividend Yield % of Royalty Pharma is 2.69%.
Royalty Pharma's Dividends per Share for the three months ended in Dec. 2024 was $0.21.
During the past 12 months, Royalty Pharma's average Dividends Per Share Growth Rate was 5.00% per year. During the past 3 years, the average Dividends Per Share Growth Rate was 7.30% per year.
During the past 8 years, the highest 3-Year average Dividends Per Share Growth Rate of Royalty Pharma was 38.70% per year. The lowest was 7.30% per year. And the median was 23.00% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
The historical data trend for Royalty Pharma's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Royalty Pharma Annual Data | |||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Dividend Yield % | Get a 7-Day Free Trial | 0.60 | 1.71 | 1.92 | 2.85 | 3.29 |
Royalty Pharma Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Dividend Yield % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
2.85 | 2.67 | 3.11 | 2.93 | 3.29 |
For the Biotechnology subindustry, Royalty Pharma's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Royalty Pharma's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Royalty Pharma's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Royalty Pharma Recent Full-Year* Dividend History
Amount | Ex-date | Record Date | Pay Date | Type | Frequency | Forex Rate |
---|---|---|---|---|---|---|
USD 0.220000 | 2025-02-21 | 2025-02-21 | 2025-03-10 | Cash Dividend | quarterly | USD:USD 1.000000 |
USD 0.210000 | 2024-11-15 | 2024-11-15 | 2024-12-10 | Cash Dividend | quarterly | USD:USD 1.000000 |
USD 0.210000 | 2024-08-16 | 2024-08-16 | 2024-09-13 | Cash Dividend | quarterly | USD:USD 1.000000 |
USD 0.210000 | 2024-05-16 | 2024-05-17 | 2024-06-14 | Cash Dividend | quarterly | USD:USD 1.000000 |
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Royalty Pharma's Trailing Annual Dividend Yield (%) for Today is calculated as
Trailing Annual Dividend Yield | = | Most Recent Full Year Dividend | / | Current Share Price |
= | 0.85 | / | 32.76 | |
= | 2.59 % |
Current Share Price is $32.76.
Royalty Pharma's Dividends per Share for the trailing twelve months (TTM) ended in Today is $0.85.
Royalty Pharma's Forward Annual Dividend Yield (%) for Today is calculated as
Forward Annual Dividend Yield | = | Forward Full Year Dividend | / | Current Share Price |
= | 0.88 | / | 32.76 | |
= | 2.69 % |
Current Share Price is $32.76.
Royalty Pharma's Dividends per Share for the forward twelve months is calculated as $0.22 * 4 = $0.88.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Royalty Pharma (NAS:RPRX) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.
Thank you for viewing the detailed overview of Royalty Pharma's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Rory B Riggs | director | 65 RAILROAD AVE, RIDGEFIELD NJ 07657 |
Avara Management Ltd | 10 percent owner | C/O GISEV FAMILY OFFICE SA, CONTRADA DI SASSELLO 2, LUGANO V8 6900 |
Terrance P. Coyne | officer: EVP & CFO | C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022 |
Pablo G. Legorreta | director, officer: CEO, Chairman of the Board | 110 E 59TH STREET, SUITE 3300, NEW YORK NY 10022 |
George W. Lloyd | officer: EVP, Investments & GC | C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022 |
Marshall Urist | officer: EVP, Research & Investments | C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022 |
Mario Germano Giuliani | director, 10 percent owner | C/O GISEV FAMILY OFFICE SA, CONTRADA DI SASSELLO 2, LUGANO V8 6900 |
James F. Reddoch | officer: EVP, Research & Investments | C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022 |
Nogra Group Sicaf Sif Gg Strategic | 10 percent owner | C/O NOGRA GROUP SICAF-SIF S.A., 18 AVENUE DE LA PORTE NEUVE, LUXEMBOURG N4 L-2227 |
Nogra Group Sicaf - Sif S.a. | 10 percent owner | 18 AVENUE DE LA PORTE NEUVE, LUXEMBOURG N4 L-2227 |
Catherine M. Engelbert | director | 110 NORTH CARPENTER STREET, CHICAGO IL 60607 |
Errol B Desouza | director | 215 COLLEGE ROAD, PARAMUS NJ 07652 |
Henry A Fernandez | director | MSCI INC., 88 PINE STREET, NEW YORK NY 10005 |
Gregory Norden | director | 16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005 |
Ted W Love | director | C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By Marketwired • 01-28-2025
By Marketwired • 11-06-2024
By Marketwired • 11-04-2024
By Marketwired • 11-14-2024
By Marketwired • 01-10-2025
By Marketwired • 02-12-2025
By GuruFocus News • 02-12-2025
By GuruFocus News • 11-09-2024
By Marketwired • 01-29-2025
By GuruFocus News • 11-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.